Neoantigen × AI
Daily research signal
№53Brief

YG-01 Neoantigen Vaccine Enters First-in-Human Glioblastoma Trial

Today's items bracket the field's two live frontiers: new indications and delivery architecture.

YGION Biomedical takes a personalized neoantigen peptide vaccine first-in-human in glioblastoma, a setting where immunotherapy has largely failed, while ex vivo work in melanoma patient cells tackles whether a single nanovaccine construct can carry multiple neoantigens without losing epitope-specific T-cell recognition.trialBioengineer.org Both target the same core bottleneck: eliciting durable responses against multiple tumor antigens in immunologically difficult tumors.trialBioengineer.org

2new stories
ClinicaltodayNew

First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma

YGION Biomedical GmbH is advancing YG-01, a personalized neoantigen peptide-based immunotherapy, into a first-in-human Phase 1 dose-escalation study (not yet recruiting) in glioblastoma patients following standard-of-care therapy. The open-label, single-arm design will assess safety, tolerability, feasibility, and immunogenicity across sequential dose cohorts to establish a recommended dose, with exploratory immune-response and clinical-outcome readouts. The signal to watch is whether a neoantigen vaccine can generate measurable immune activity in GBM, a tumor type that has resisted conventional immunotherapy and adds CNS delivery and immune-suppression hurdles.

clinicaltrials · today · YGION Biomedical GmbH

01

01
AI / Methods5 days agoNew

Tailored Nanovaccines Stimulate Neoantigen-Specific T-Cell Responses in Melanoma Patient Cells - Bioengineer.org

Ex vivo work in PBMCs from melanoma patients shows tailored polyethyleneimine-PLGA nanovaccines functionalized with poly(I:C) significantly enhanced neoantigen-specific T-cell activation, delivering patient-specific multiepitope neoantigen peptides and adjuvant in a single formulation. The platform is built to test an unresolved design question for the field: whether combining multiple neoantigens in one construct preserves T-cell recognition of individual neoepitopes. This is laboratory-stage immunogenicity data, not clinical validation, but a positive answer would support consolidating personalized vaccine manufacturing into a single construct per patient rather than peptide pools. The unmet need is framed by a projection of more than 510,000 new melanoma cases and 96,000 deaths worldwide by 2040.

news · 5 days ago · Bioengineer.org